PortfoliosLab logoPortfoliosLab logo
ENVB vs. FMED
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

ENVB vs. FMED - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Enveric Biosciences Inc (ENVB) and Fidelity Disruptive Medicine ETF (FMED). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ENVB achieves a -59.23% return, which is significantly lower than FMED's -4.75% return.


ENVB

1D
-3.27%
1M
-34.22%
YTD
-59.23%
6M
-72.39%
1Y
-89.81%
3Y*
-87.52%
5Y*
-85.10%
10Y*
-74.86%

FMED

1D
0.90%
1M
7.10%
YTD
-4.75%
6M
-6.17%
1Y
8.53%
3Y*
0.73%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ENVB vs. FMED - Yearly Performance Comparison


2026 (YTD)202520242023
ENVB
Enveric Biosciences Inc
-59.23%-94.37%-72.43%-65.79%
FMED
Fidelity Disruptive Medicine ETF
-4.75%9.69%2.29%-3.59%

Correlation

The correlation between ENVB and FMED is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.21

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (All Time)
Calculated using the full available price history since Jun 12, 2023

0.24

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ENVB vs. FMED — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ENVB
ENVB Risk / Return Rank: 1111
Overall Rank
ENVB Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
ENVB Sortino Ratio Rank: 1212
Sortino Ratio Rank
ENVB Omega Ratio Rank: 1212
Omega Ratio Rank
ENVB Calmar Ratio Rank: 22
Calmar Ratio Rank
ENVB Martin Ratio Rank: 1010
Martin Ratio Rank

FMED
FMED Risk / Return Rank: 1515
Overall Rank
FMED Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
FMED Sortino Ratio Rank: 1616
Sortino Ratio Rank
FMED Omega Ratio Rank: 1515
Omega Ratio Rank
FMED Calmar Ratio Rank: 1414
Calmar Ratio Rank
FMED Martin Ratio Rank: 1414
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ENVB vs. FMED - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Enveric Biosciences Inc (ENVB) and Fidelity Disruptive Medicine ETF (FMED). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ENVBFMEDDifference
Sharpe ratioReturn per unit of total volatility

-0.96

Sortino ratioReturn per unit of downside risk

-1.80

Omega ratioGain probability vs. loss probability

0.87

1.09

-0.22

Calmar ratioReturn relative to maximum drawdown

-0.98

0.47

-1.45

Martin ratioReturn relative to average drawdown

-1.34

1.03

-2.38

ENVB vs. FMED - Sharpe Ratio Comparison

The current ENVB Sharpe Ratio is -0.51, which is lower than the FMED Sharpe Ratio of 0.44. The chart below compares the historical Sharpe Ratios of ENVB and FMED, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ENVB vs. FMED - Drawdown Comparison

The maximum ENVB drawdown since its inception was -100.00%, which is greater than FMED's maximum drawdown of -21.84%. Use the drawdown chart below to compare losses from any high point for ENVB and FMED.


Loading charts...

Drawdown Indicators


ENVBFMEDDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-21.84%

-78.16%

Max Drawdown (1Y)

Largest decline over 1 year

-91.49%

-18.33%

-73.16%

Max Drawdown (3Y)

Largest decline over 3 years

-99.81%

-21.84%

-77.97%

Max Drawdown (5Y)

Largest decline over 5 years

-100.00%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

Current Drawdown

Current decline from peak

-100.00%

-10.64%

-89.36%

Average Drawdown

Average peak-to-trough decline

-86.07%

-7.09%

-78.98%

Ulcer Index

Depth and duration of drawdowns from previous peaks

66.73%

8.27%

+58.46%

Volatility

ENVB vs. FMED - Volatility Comparison

Enveric Biosciences Inc (ENVB) has a higher volatility of 21.07% compared to Fidelity Disruptive Medicine ETF (FMED) at 7.50%. This indicates that ENVB's price experiences larger fluctuations and is considered to be riskier than FMED based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ENVBFMEDDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.07%

7.50%

+13.57%

Volatility (6M)

Calculated over the trailing 6-month period

105.59%

15.01%

+90.58%

Volatility (1Y)

Calculated over the trailing 1-year period

175.01%

19.37%

+155.64%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

155.96%

18.57%

+137.39%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

164.65%

18.57%

+146.08%

Dividends

ENVB vs. FMED - Dividend Comparison

Neither ENVB nor FMED has paid dividends to shareholders.


PositionTTM20252024
ENVB
Enveric Biosciences Inc
0.00%0.00%0.00%
FMED
Fidelity Disruptive Medicine ETF
0.00%0.00%0.46%

Frequently Asked Questions


ENVB and FMED have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ENVB has higher volatility (21.07%) compared to FMED (7.50%). In terms of maximum drawdown, ENVB dropped -100.00% vs FMED's -21.84%.

FMED currently has the higher Sharpe Ratio (0.44 vs -0.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ENVB and FMED

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer